Skip to main content
SpringerLink
Log in

Hepatitis als Reisekrankheit

Hepatitis as a travelers’ disease

  • Schwerpunkt: Reisemedizin
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Jedes Jahr reisen über 50 Mio. Menschen aus industrialisierten Staaten in Länder mit hoher Prävalenz an oral-fäkal und sexuell übertragbaren Hepatitiden. Für sie ist das Risiko einer Infektion mit dem Hepatitis-A-Virus je nach Lebensbedingungen, der Dauer des Aufenthalts und dem Reiseziel bis zu 10fach erhöht. Vor allem im asiatischen Raum kann sich der Reisende mit dem Hepatitis-E-Virus infizieren. Sexuelle Promiskuität mit ungeschütztem Geschlechtsverkehr ist der Hauptrisikofaktor für eine im Ausland erworbene Hepatitis-B-Infektion. Dennoch sind sich die meisten Reisenden dieser Gefahren nicht bewusst. Der vorliegende Beitrag bespricht praxisrelevante Aspekte der auf Reisen erworbenen viralen Hepatitiden.

Abstract

Every year over 50 million people travel from industrialized countries to areas with high prevalence of oral-fecal and sexually transmissible forms of viral hepatitis. The risk of infection with hepatitis A is associated with the standard of living, the length of stay, and the area of destination. Acute hepatitis E is predominantly transmitted in India and other Asian countries. The main risk factors for the acquisition of hepatitis B are sexual promiscuity and unprotected sexual intercourse. This report provides detailed information on the risk of hepatitis in travelers, available vaccination schedules, clinical and laboratory diagnostic features, and necessary therapeutic aspects in cases of ongoing acute viral hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8

Literatur

  1. (2003) Branchenbild Nr. 3. Gruner & Jahr, Hamburg

  2. Craig AS, Schaffner W (2004) Prevention of hepatitis A with hepatitis A vaccine. N Engl J Med 350: 476–481

    Article  CAS  PubMed  Google Scholar 

  3. Koff RS (1995) Seroepidemiology of hepatitis A in the United States. J Infect Dis 171: S19–23

    PubMed  Google Scholar 

  4. Lemon SM (2000) Hepatitis A virus. Update on viral hepatitis. American Association for the Study of Liver Diseases, p 48

  5. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW (1985) Frequency of illness associated with epidemic hepatitis A virus infections in adults. A J Epidemiol 122: 226–233

    CAS  Google Scholar 

  6. Steffen R (1995) Hepatitis A in travelers: The European experience. J Infect Dis 171: S24–28

    PubMed  Google Scholar 

  7. Manns MP, Schüler A (1999) Reisen und Hepatitis. Internist 40: 1137–1142

    Article  CAS  PubMed  Google Scholar 

  8. Gillies P, Slack R, Stoddart N, Convay S (1992) HIV-related risk behaviour in UK holiday-makers. AIDS 5: 339–441

    Google Scholar 

  9. Hawkes S, Hart GJ, Johnson AM et al. (1994) Risk behaviour and HIV prevalence in interregional travelers. AIDS 8: 247–252

    CAS  PubMed  Google Scholar 

  10. Moore J, Beeker C, Harrison JS, Eng TR, Doll LS (1995) HIV risk behaviour among Peace Corps volunteers. AIDS 9: 795

    CAS  PubMed  Google Scholar 

  11. Zwar NA (2003) Hepatitis risk and vaccination among Australian travellers overseas. M J Aust 178: 469–70

    Google Scholar 

  12. Herck KV, Damme PV, Castelli F et al. (2004) Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 11: 3–7

    PubMed  Google Scholar 

  13. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, Type A. National Centers for Infectious Diseaseshttp://www.travellers-health.com

  14. Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E (1994) Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 113: 113–120

    CAS  PubMed  Google Scholar 

  15. Webster G, Barnes E, Dusheiko G (2001) Protecting travelers from hepatitis A. Vaccine shoueld be used for almost every occasion when prevention is required. BMJ 322: 1194–1195

    Article  CAS  PubMed  Google Scholar 

  16. Ciccozzi M, Tosti ME, Gallo G et al. (2002) Risk of hepatitis A infection following travel. J Viral Hepatitis 9: 460–465

    Article  Google Scholar 

  17. Steffen R (1991) Travel medicine 2. In: Lobel HO, Steffen R, Kozarsky PE (eds) Proceedings of the second conference on international travel medicine. Atlanta, USA

  18. Bell BP, Shapiro CN, Alter MJ et al. (1998) The diverse patterns of hepatitis A epidemiology in the United States—implication for vaccination strategies. J Infect Dis 178: 1579–1584

    Article  PubMed  Google Scholar 

  19. Hadem J (2003) Immunopathogenesis and treatment of hepatitis A. In: Gershwin ME, Vierling JM, Manns MP (eds) Liver immunology. Hanley & Belfus, Philadelphia, pp 185–201

  20. (2000) Hepatitis A—Erkennung und Verhütung: Merkblatt für Ärzte. Bundesgesundheitsblatt 43: 257–259

    Google Scholar 

  21. Feinstone SM, Kapikian AZ, Purcell RH (1973) Hepatitis A: Detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 182: 1026–1028

    PubMed  Google Scholar 

  22. Innis BL, Snitbhan R, Kunasol P et al. (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271: 1328–1334

    Article  PubMed  Google Scholar 

  23. Werzberger A, Mensch B, Kuter B et al. (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327: 453–457

    PubMed  Google Scholar 

  24. Lee SD, Chan CY, Yu MI et al. (1997) Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 52: 215–218

    Article  CAS  PubMed  Google Scholar 

  25. Keeffe EB, Iwarson S, McMahon BJ et al. (1998) Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27: 881–886

    CAS  PubMed  Google Scholar 

  26. Arslan M, Wiesner RH, Poterucha JJ, Zein NN (2001) Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72: 272–276

    Article  CAS  PubMed  Google Scholar 

  27. Wolters B, Junge U, Dziuba S, Roggendorf M (2003) Immunogenicity of combinded hepatitis A and B vaccine in elderly persons. Vaccine 21: 3623–3628

    Article  CAS  PubMed  Google Scholar 

  28. STIKO (2000) Mitteilungen der Ständigen Impfkommission (STIKO) zur Hepatitis-A- und -B-Impfung. Epidemiol Bull 10: 81

    Google Scholar 

  29. Fishbain JT, Eckart RE, Harner KC, Hospenthal DR (2002) Empiric immunization versus serologic screening: developing a cost-effective strategy für the use of hepatitis A immunization in travelers. J Travel Med 9: 71–75

    PubMed  Google Scholar 

  30. Hadem J, Wedemeyer H, Scholz H, Manns MP (2004) Chronische Hepatitis. In: Adam D, Doerr HW, Link H, Lode H (Hrsg) Die Infektiologie. Springer, Berlin Heidelberg New York Tokio, S 513–533

  31. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type B. National Centers for Infectious Diseaseshttp://www.travellers-health.com

  32. Guidotti LG, Chisari FV (2000) Cytokine-mediated control of viral infections. Virology 273: 221–227

    Article  CAS  PubMed  Google Scholar 

  33. Manns MP, Hadem J, Wedemeyer H (2004) Hepatitis B virus: where are we and where are we going? Methods Mol Med 96: 415–444

    CAS  PubMed  Google Scholar 

  34. Hadem J, Wiegand J, Manns MP (2002) Chronische Hepatitiden—wann und wie therapieren? Hausarzt 20: 54–60

    Google Scholar 

  35. STIKO (2003) Empfehlungen der ständigen Impfkommission (STIKO) am Robert-Koch-Institut. Epidemiol Bull 32

  36. Margolis H (2000) Hepatitis B vaccine. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 88–91

  37. Wolters B, Junge U, Dziuba S, Roggendorf M (2003) Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21: 3623–3628

    Article  CAS  PubMed  Google Scholar 

  38. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC (2001) Adult hepatitis B vaccination using a novel triple antigen recombination vaccine. Hepatology 34: 372–376

    Article  CAS  PubMed  Google Scholar 

  39. Nothdurft HD, Dietrich M, Zuckerman JN, Kobloch J, Kern P, Vollmar J, Sanger R (2002) A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 15: 1157–1162

    Article  Google Scholar 

  40. Casey J (2000) Hepatitis D virus. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 83–87

  41. Purcell RH (2000) Hepatitis E virus. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 61–67

  42. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type E. National Centers for Infectious Diseaseshttp://www.travellers-health.com

  43. Teich N, Tannapfel A, Ammon A, Ruf BR, van der Poel WH, Mossner J, Liebert UG (2003) Sporadic acute hepatitis E in Germany: an underdiagnosed phenomenon? Z Gastroenterol 41: 419–423

    Article  CAS  PubMed  Google Scholar 

  44. Favorov MO, Kosoy MY, Tsarev SA, Childs JE, Margolis HS (2000) Prevalence of antibody to hepatitis E virus among rodents in the United States. J Infect Dis 181: 449–455

    Article  CAS  PubMed  Google Scholar 

  45. Aggarwal R, Krawczynski K (2000) Hepatitis E: an overview and recent advances in clinical and laboratory research. J Gastroenterol Hepatol 15: 9–20

    Article  CAS  PubMed  Google Scholar 

  46. Clayson ET, Myint KS, Snitbhan R et al. (1995) Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 172: 927–933

    CAS  PubMed  Google Scholar 

  47. Jilg W (2004) Hepatitis-E-Virus. In: Adam D, Doerr HW, Link H, Lode H (Hrsg) Die Infektiologie. Springer, Berlin Heidelberg New York Tokio, S 884–885

  48. Khuroo MS, Dar MY (1992) Hepatitis E: evidence for person-to-person transmission and inability of low dose immune serum globulin from an Indian source to prevent it. Indian J Gastroenterol 11: 113–116

    CAS  PubMed  Google Scholar 

  49. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type C. National Centers for Infectious Diseaseshttp://www.travellers-health.com

  50. Jaeckel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with interferon-α2b. N Engl J Med 345: 1452–1457

    Google Scholar 

  51. Robert-Koch-Institut (2001) Zu Übertragungswegen und Übertragungsfaktoren der Hepatitis A—Ergebnisse einer epidemiologischen Untersuchung in Hamburg. Epidemiol Bull 50: 383–384

    Google Scholar 

  52. Maier K, Gabriel P, Koscielniak E et al. (1988) Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol 62: 3756–3763

    PubMed  Google Scholar 

  53. Ostapowicz G, Fontana RJ, Schiodt FV et al. (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137: 947–954

    PubMed  Google Scholar 

  54. Werzberger A, Mensch B, Nalin DR, Kuter BJ (2002) Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years follow-up after the Monroe field trial of VAQTA. Vaccine 20: 1699–1701

    Article  PubMed  Google Scholar 

  55. Van Damme P, Banatvala J, Fay O et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362: 1065–1071

    Article  PubMed  Google Scholar 

  56. Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S (2003) Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 41: 983–990

    Article  CAS  PubMed  Google Scholar 

  57. Tei S, Kitajima N, Takahashi K, Mishiro S (2003) Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362: 371–373

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Keine Angaben

Author information

Authors and Affiliations

  1. Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

    J. Hadem,  H. Wedemeyer & M. P. Manns

  2. Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule, Carl-Neuberg-Straße 1, 30625, Hannover

    H. Wedemeyer

Authors
  1. J. Hadem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wedemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. P. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Wedemeyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hadem, J., Wedemeyer, H. & Manns, M.P. Hepatitis als Reisekrankheit. Internist 45, 655–668 (2004). https://doi.org/10.1007/s00108-004-1197-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-004-1197-4

Schlüsselwörter

Keywords

Search

Navigation